Mylan says EpiPen pretax profits 60% higher than it told Congress

Mylan said on Monday the auto-injector EpiPen's pretax profits were 60 percent higher than it told Congress, according to Dow Jones. Without a tax-related reduction, the pharmaceutical company's profits on the EpiPen two-pack would be about $160, higher than the $100 figure the company gave Congress. The company said any lack of clarity was not intentional.